William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and reach over $1 billion in global sales.

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements. In the treatment of newly diagnosed biliary tract cancer, the current standard ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Wednesday granted accelerated approval to zanidatamab ...

When do you have tests for bile duct cancer? Bile duct cancer is also called cholangiocarcinoma. It is a rare type of cancer that develops in the bile ducts. Most people are diagnosed with bile duct ...

Adding liposome-encapsulated irinotecan to standard chemotherapy failed to improve survival as second-line treatment for advanced biliary cancer, a small randomized study showed. Median ...

Gallbladder cancer and cholangiocarcinoma are different types of biliary tract cancer. They affect the same system in the body and cause similar symptoms, but they may require different treatments.

Doctors in the UK are hoping to transform the lives of people with deadly bile duct cancer. A new study – which has shown promising early results – matches the patient’s tumour to one or more of seven ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...